In November, we added 119 citations in DIDB, including 61 in vitro (with 24 articles published in November 2022) and 58 in vivo articles (with 34 articles published in November 2022).
Three recently approved NDAs and BLAs were also added: futibatinib (LYTGOBI), teclistamab (TECVAYLI), tremelimumab (IMJUDO).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.